The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHiscox Regulatory News (HSX)

Share Price Information for Hiscox (HSX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,166.00
Bid: 1,167.00
Ask: 1,171.00
Change: -4.00 (-0.34%)
Spread: 4.00 (0.343%)
Open: 1,171.00
High: 1,175.00
Low: 1,149.00
Prev. Close: 1,170.00
HSX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Announcement of share repurchase programme

5 Mar 2024 07:01

RNS Number : 5484F
Hiscox Ltd
05 March 2024
 

 

Announcement of share repurchase programme

 

Hamilton, Bermuda (5 March 2024) - Hiscox Ltd ("Hiscox" or the "Company") today announces it will commence a buyback of its ordinary shares of 6.5 pence each ("Ordinary Shares") for a maximum aggregate consideration of $150 million (the "Programme"), in order to return additional capital to shareholders. The Programme will commence today with an initial tranche of $75 million.

 

Hiscox has entered into a non-discretionary agreement with Peel Hunt LLP ("Peel Hunt") to conduct the initial tranche of the Programme with the Company subsequently purchasing its Ordinary Shares from Peel Hunt. Under this arrangement, Peel Hunt will act as principal and make trading decisions independently of Hiscox, except for Hiscox's ability to terminate Peel Hunt's mandate in certain limited circumstances.

 

The maximum aggregate consideration under the initial tranche is $75 million (excluding expenses). The Company intends to cancel such Ordinary Shares purchased. The sole purpose of the Programme is to reduce Hiscox's share capital.

 

Purchases under the Programme will take place in open market transactions and may be made from time to time by Peel Hunt, depending on market conditions, share price and trading volumes. The Programme will be effected under the authority granted by shareholders at the Company's 2023 Annual General Meeting held on 11 May 2023 (and any subsequent authority) and, as at the date of this announcement, the maximum number of shares that may be repurchased under the Programme is 34,655,073 Ordinary Shares. Any purchases contemplated by this announcement will be carried out on the London Stock Exchange and/or other recognised investment exchange(s). The Programme's initial tranche will end when the maximum aggregate consideration reaches $75 million or as otherwise terminated.

 

The Programme will be conducted within the parameters prescribed by the Market Abuse Regulation 596/2014 and the Commission Delegated Regulation (EU) 2016/1052 as it forms part of UK law pursuant to the UK's European Union (Withdrawal) Act 2018 and the Market Abuse (Amendment) (EU Exit) Regulations 2019) as well as applicable laws and the regulations of the UK Financial Conduct Authority (including Chapter 12 of the Listing Rules). Any repurchase of shares will be announced no later than 7:30 a.m. on the business day following the calendar day on which the repurchase occurred.

 

There is no guarantee that the Programme will be implemented in full.

 

The Company intends to enter into arrangements to commence a second tranche of the share buyback programme with Citigroup Global Markets Limited for a maximum aggregate consideration of $75 million in due course.

 

Aki Hussain, Group Chief Executive Officer, Hiscox Ltd, commented:

 

"Our business delivered record profits of $625.9 million and ROE of 21.8%[1] in 2023. This excellent result has led to very strong capital generation, which we are deploying for further growth in all parts of the business in addition to a special return to shareholders of $150 million. The buyback will commence immediately and illustrates our objective of delivering strong returns to our shareholders."

 

ENDS

 

 

For further information

Investors and analysts

Yana O'Sullivan, Director of Investor Relations, London +44 (0)20 3321 5598

Marc Wetherhill, Group Company Secretary, Bermuda +1 441 278 8300

 

Media

Eleanor Orebi Gann, Group Director of Communications, London +44 (0)20 7081 4815

Simone Selzer, Brunswick +44 (0)20 7404 5959

Tom Burns, Brunswick +44 (0)20 7404 5959

Notes to editors

About The Hiscox Group

Hiscox is a global specialist insurer, headquartered in Bermuda and listed on the London Stock Exchange (LSE:HSX). Our ambition is to be a respected specialist insurer with a diverse portfolio by product and geography. We believe that building balance between catastrophe-exposed business and less volatile local specialty business gives us opportunities for profitable growth throughout the insurance cycle. 

The Hiscox Group employs over 3,000 people in 14 countries, and has customers worldwide. Through the retail businesses in the USA, UK, Europe and Asia, we offer a range of specialist insurance products in commercial and personal lines. Internationally-traded, bigger-ticket business and reinsurance is underwritten through Hiscox London Market and Hiscox Re & ILS.

Our values define our business, with a focus on people, courage, ownership and integrity. We pride ourselves on being true to our word and our award-winning claims service is testament to that. For more information, visit www.hiscoxgroup.com.

 


[1]Excludes impact of Bermuda Deferred Tax Asset.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSQKQBDBBKBDNK
Date   Source Headline
8th Mar 20247:00 amRNSTransaction in Own Shares
7th Mar 20247:30 amRNSSyndicates 33 and 6104 – results and estimates
7th Mar 20247:00 amRNSTransaction in Own Shares
6th Mar 20247:00 amRNSTransaction in Own Shares
5th Mar 20247:01 amRNSAnnouncement of share repurchase programme
5th Mar 20247:00 amRNSFull Year Results
19th Feb 20245:48 pmRNSTR-1 Standard form-notification major shareholding
1st Feb 20244:34 pmRNSTotal Voting Rights
8th Jan 20243:07 pmRNSTotal Voting Rights
12th Dec 20234:44 pmRNSDirector/PDMR Shareholding
1st Dec 20234:40 pmRNSTotal Voting Rights
10th Nov 202311:30 amRNSSyndicates 33 and 6104 – results and estimates
8th Nov 20237:00 amRNSQ3 2023 Trading Statement
1st Nov 20235:20 pmRNSTotal Voting Rights
2nd Oct 20234:47 pmRNSTotal Voting Rights
27th Sep 20237:00 amRNSDivestment of DirectAsia
25th Sep 202312:30 pmRNSDirector/PDMR Shareholding
25th Sep 20239:00 amRNSApplication to be admitted to the Official List
12th Sep 20235:22 pmRNSAnnouncement of Scrip Reference Share Price
1st Sep 20237:00 amRNSDirector/PDMR Shareholding
11th Aug 20237:30 amRNSSyndicates 33 and 6104 - results and estimates
10th Aug 20237:00 amRNSDirector/PDMR Shareholding
4th Jul 20231:23 pmRNSTotal Voting Rights
21st Jun 20233:23 pmRNSDirector/PDMR Shareholding
16th Jun 202312:35 pmRNSDirector PDMR Shareholding
14th Jun 20231:19 pmRNSStandard form for notification of major holdings
13th Jun 20232:28 pmRNSDirector/PDMR Shareholding
9th Jun 20231:56 pmRNSApplication to be Admitted to Official List
9th Jun 202312:19 pmRNSApplication to be Admitted to Official List
8th Jun 20237:00 amRNSIFRS 17 restated results 2022
1st Jun 20235:10 pmRNSTotal Voting Rights
1st Jun 202312:12 pmRNSAnnouncement of Scrip Reference Share Price
30th May 20234:05 pmRNSDirector/PDMR Shareholding
30th May 20237:00 amRNSHiscox appoints Jonathan Bloomer Chair designate
23rd May 20233:26 pmRNSTR-1:Standard form-notification major shareholding
22nd May 202312:25 pmRNSTR-1:Standard form-notification major shareholding
15th May 20231:01 pmRNSSyndicates 33 and 6104 – results and estimates
12th May 20237:01 amRNSHiscox appoints new Independent Non Exec Director
12th May 20237:00 amRNSAGM RESULTS
11th May 20235:33 pmRNSTR-1 Standard form-notification major shareholding
9th May 202312:23 pmRNSTR-1:Standard form-notification major shareholding
4th May 20237:00 amRNSQ1 2023 Trading Statement
2nd May 20235:00 pmRNSTotal Voting Rights
5th Apr 20232:19 pmRNSDirector/PDMR Shareholding
3rd Apr 20234:08 pmRNSTotal Voting Rights
24th Mar 20231:30 pmRNSNotice of 2023 AGM & 2022 Annual Report & Accounts
22nd Mar 202311:03 amRNSDirector/PDMR Shareholding
9th Mar 20233:46 pmRNSDirector/PDMR Shareholding
9th Mar 20237:00 amRNSSyndicates 33 and 6104 – results and estimates
8th Mar 20237:01 amRNSFull Year Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.